Previous 10 | Next 10 |
EAGAN, Minn., May 02, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) l...
2023-04-25 13:30:38 ET Gainers: CXApp ( CXAI ) +82% . Petros Pharmaceuticals ( PTPI ) +49% . LogicMark ( LGMK ) +28% . Apollomics ( APLM ) +23% . The Aaron's Company ( AAN ) +18% . Baudax Bio ( BXRX ) +18% . Predi...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has an...
2023-04-20 17:24:19 ET Predictive Oncology ( NASDAQ: POAI ) on Thursday said it would effect a 1-for-20 reverse stock split. The stock split will become effective on April 24. "The reverse stock split is primarily intended to bring the Company into compliance with the mini...
Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that it is effecting a reverse stock s...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, h...
2023-04-14 10:38:00 ET Thanks to key economic data, this has been one of the wildest weeks in the stock market. Whether you’re trading penny stocks or higher-priced companies, it is almost impossible not to notice all macro catalysts in motion. Whether it was March CPI inflation ...
Predictive Oncology (NASDAQ: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, h...
EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA)...
Predictive Oncology (NASDAQ: POAI) , a science-driven company on the leading edge of oncology drug discovery and development, today announced that it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases. According to ...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...